These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 21393563)

  • 1. An economic evaluation of a laboratory monitoring program for renin-angiotensin system agents.
    Smith DH; Raebel MA; Chan KA; Johnson ES; Petrik AF; Weiss JR; Yang X; Feldstein A
    Med Decis Making; 2011; 31(2):315-24. PubMed ID: 21393563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data.
    van Leent MW; Stevanović J; Jansman FG; Beinema MJ; Brouwers JR; Postma MJ
    PLoS One; 2015; 10(8):e0135054. PubMed ID: 26241880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dedicated Perioperative Hip Fracture Comanagement Programs are Cost-effective in High-volume Centers: An Economic Analysis.
    Swart E; Vasudeva E; Makhni EC; Macaulay W; Bozic KJ
    Clin Orthop Relat Res; 2016 Jan; 474(1):222-33. PubMed ID: 26260393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion.
    Wali AR; Park CC; Brown JM; Mandeville R
    Neurosurg Focus; 2017 Mar; 42(3):E11. PubMed ID: 28245686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of obstructive sleep apnea screening for patients with diabetes or chronic kidney disease.
    Okubo R; Kondo M; Hoshi SL; Yamagata K
    Sleep Breath; 2015 Sep; 19(3):1081-92. PubMed ID: 25643768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial.
    Henderson C; Knapp M; Fernández JL; Beecham J; Hirani SP; Cartwright M; Rixon L; Beynon M; Rogers A; Bower P; Doll H; Fitzpatrick R; Steventon A; Bardsley M; Hendy J; Newman SP;
    BMJ; 2013 Mar; 346():f1035. PubMed ID: 23520339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
    Ferguson TW; Tangri N; Tan Z; James MT; Lavallee BDA; Chartrand CD; McLeod LL; Dart AB; Rigatto C; Komenda PVJ
    Kidney Int; 2017 Jul; 92(1):192-200. PubMed ID: 28433383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
    Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
    Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients.
    Aspinall SL; Smith KJ; Good CB; Zhao X; Stone RA; Tonnu-Mihara IQ; Cunningham FE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):653-60. PubMed ID: 24092553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seven-year cost-effectiveness of ProDisc-C total disc replacement: results from investigational device exemption and post-approval studies.
    Radcliff K; Lerner J; Yang C; Bernard T; Zigler JE
    J Neurosurg Spine; 2016 May; 24(5):760-8. PubMed ID: 26824587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
    Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
    J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
    Lu L; Peters J; Roome C; Stein K
    BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of therapeutic drug monitoring.
    Vozeh S
    Clin Pharmacokinet; 1987 Sep; 13(3):131-40. PubMed ID: 3117472
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-utility analysis of sodium polystyrene sulfonate vs. potential alternatives for chronic hyperkalemia.
    Little DJ; Nee R; Abbott KC; Watson MA; Yuan CM
    Clin Nephrol; 2014 Apr; 81(4):259-68. PubMed ID: 24656316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.